Abstract
Significant improvements in clinical outcomes for lung cancer patients have been achieved over the past decade, and this is a result of the introduction of targeted therapies in molecularly selected subpopulations of patients, as well as the unprecedented efficacy of immunotherapy. Despite this, only a small proportion of patients respond to immunotherapy and few patients achieve long-term survival. Several epigenetic modifications have been associated with the development and progression of many cancers, including lung cancer. The discovery of this link between epigenetic modifications and cancer fueled the development of agents to target changes in the epigenome. Many of these epigenetic agents have now been approved for use in diseases, most commonly in hematological malignancies. In addition, there is a growing body of research, including preclinical work and early-phase clinical trials, demonstrating the use of epigenetic-targeted drugs for the treatment of lung cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
